GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Panacea Biotec receives LoA from CMSS
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Subscribe To Our Newsletter & Stay Updated
